Journal of Antimicrobial Chemotherapy (2002) 49, 49-50
© 2002 The British Society for Antimicrobial Chemotherapy
Supplement |
Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections
Division of Oncologic Thoracic Surgery, Istituto Nazionale Tumori, Via Venezian 1, 20133 MI, Milano, Italy
Abstract
A prospective study of the treatment of fungal infections with low-dose AmBisome enrolled 36 of 52 patients with thoracic malignancies who developed pulmonary fungal infections in the National Cancer Centre, Milan, over a 3.5 year period. Thirty-three high-risk patients had received standard prophylaxis with iv fluconazole. In these patients, symptoms indicating deep mycosis were detected after 7–9 days of primary prophylactic therapy. Another three patients, not treated with fluconazole, showed similar symptoms. Bronchoalveolar lavage, blood culture and/or CT scan of chest diagnosed invasive aspergillosis in 29 patients and deep invasive Candida infection in seven. AmBisome was given at 1–2.2 mg/kg/day iv for 10 days to avoid or decrease toxicity normally induced by amphotericin B. The fungal infection was eradicated in all 36 patients. Negative cultures were obtained after 5 or 6 days of antifungal treatment. No adverse reactions attributed to AmBisome were detected. After a follow up of 5–48 months, 30 patients were still alive. Six patients had died, two due to adult respiratory distress syndrome and four due to progression of cancer. No mycotic relapses or reinfections were detected during follow up. In a subset of critically ill patients with thoracic malignancies, the administration of low-dose liposomal amphotericin B (AmBisome) resulted in complete eradication of pulmonary Aspergillus and Candida infections, and was remarkably well tolerated.
Notes
* Tel: 39-02-2390-788; Fax: 39-02-2360-486; E-mail: lequaglie{at}istitutotumori.mi.it
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Wu, C. Xia, X. Du, X. Cao, and J. Shen Influence of Anti-FloR Antibody on Florfenicol Accumulation in Florfenicol-Resistant Escherichia coli and Enzyme-Linked Immunosorbent Assay for Detection of Florfenicol-Resistant E. coli Isolates J. Clin. Microbiol., February 1, 2006; 44(2): 378 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Doublet, S. Schwarz, C. Kehrenberg, and A. Cloeckaert Florfenicol Resistance Gene floR Is Part of a Novel Transposon Antimicrob. Agents Chemother., May 1, 2005; 49(5): 2106 - 2108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Blickwede and S. Schwarz Molecular analysis of florfenicol-resistant Escherichia coli isolates from pigs J. Antimicrob. Chemother., January 1, 2004; 53(1): 58 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Meunier, S. Baucheron, E. Chaslus-Dancla, J.-L. Martel, and A. Cloeckaert Florfenicol resistance in Salmonella enterica serovar Newport mediated by a plasmid related to R55 from Klebsiella pneumoniae J. Antimicrob. Chemother., April 1, 2003; 51(4): 1007 - 1009. [Abstract] [Full Text] [PDF]
|
|